Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The National Institute for Health and Care Excellence (NICE) has approved a one-off gene editing therapy to treat severe sickle cell disease (SCD) in people 12 years and over. In final draft guidance1 ...